L'équipe CCM recrute un postdoc en chimie organique pour 2021

27 October 2020

Scientific Context: Chronic pain is a major health problem and a socio-economical burden. Despite sustained research efforts and the increasing diversity of available therapeutic approaches, most medications fall short in alleviating chronic pain syndromes. As a matter of fact, opiates and their derivatives, which target the mu-opioid receptor, still represent the most effective means of treating severe pain across a wide range of conditions. Despite their undeniable benefit for treating severe acute pain, opioids still lack effectiveness for long-term therapy. Indeed, repeated administration of opioids exacerbates adverse effects, such as pain hypersensitivity also known as opioid-induced hyperalgesia (OIH), which in turn impairs the analgesic efficacy (tolerance) and triggers the need for dose-escalation. In addition to pain hypersensitivity, risks of respiratory depression, addiction potential and constipation considerably affect the patient’s quality of life and can lead to fatal consequences. This is particularly true in the USA where almost half a million Americans have died from drug overdose (essentially opiates) since 2000. Altogether, these data point to the urgent need to develop novel analgesics with reduced side effects. In the last years, we have been working on the hypothesis that side effects induced by chronic administration of opiates, including OIH and analgesic tolerance result from the imbalance of a homeostatic equilibrium between opioid anti-nociceptive systems and anti-opioid pro-nociceptive systems. From this hypothesis, we are developing antagonists targeting a specific family of GPCRs, named RFamides, in order to block OIH and analgesic tolerance. This approach would be a crucial alternative to improve the treatment of acute and chronic pains.

In this context, applications are open for a postdoctoral position funded by ANR. The position will be based at Laboratoire d’Innovation Thérapeutique (UMR7200, Faculty of pharmacy) in Illkirch, near Strasbourg (France). The team is part of the LabEx MEDALIS for drug discovery and the Ecole Universitaire de Recherche Interdisciplinaire sur la Douleur (EURIDOL). The research program will focus on the optimization of heterocyclic antagonists targeting RFamide receptors.

 

Skills/Qualifications: Candidates for this postdoctoral fellowship must hold a PhD degree in organic chemistry, experience in heterocyclic chemistry will be appreciated. Autonomy and strong reliability are highly required. All applicants must be able to communicate fluently in French and/or English. The position is available for a period of at least 12 months, starting from beginning of 2021

 

Selection process: Candidates send a CV, a scientific track record and a motivation letter

Contact: Dr Frédéric BIHEL, fbihel@unistra.fr , +33 (0)368854130

Application deadline : November 30th, 2020